Effect of Albumin Concentration and Timing on Acute Kidney Injury After Adult Cardiac Surgery: A Systematic Review and Meta-Analysis

April 30, 2026 No Comments

This systematic review and meta-analysis evaluated whether hyperoncotic 20%–25% human albumin affects acute kidney injury after adult on-pump cardiac surgery. Across four studies including 6,651 patients, albumin was associated with a modest but consistent increase in postoperative AKI risk compared with crystalloids or 4%–5% albumin. Risk appeared similar whether albumin was given during surgery or within 24 hours afterward, supporting cautious, selective use.

Incidence, Risk Factors and Outcomes of Postoperative Acute Kidney Injury Requiring Dialysis After Cardiac Surgery: A Retrospective Study from the National Heart Institute of Malaysia

April 6, 2026 No Comments

This retrospective Malaysian cohort study examined 6,779 adult cardiac surgery patients and found that 4.5% developed postoperative acute kidney injury requiring dialysis. Risk was higher in patients with chronic kidney disease, urgent surgery, diabetes, reoperation, and longer ICU stay. Dialysis-requiring AKI was linked to sharply increased mortality, especially among patients without baseline CKD, highlighting the need for earlier renal risk stratification and kidney-protective perioperative care.

Hemolysis and Kidney Injury Risk After Cardiac Surgery

Hemolysis and Acute Kidney Injury Following Cardiac Surgery With Cardiopulmonary Bypass in Patients With Preexisting Renal Dysfunction

March 23, 2026 No Comments

This study examines whether hemolysis, measured by cell-free hemoglobin (CFHb), predicts acute kidney injury (AKI) after cardiac surgery in patients with preexisting renal dysfunction. Among 89 patients, 21% developed AKI. Although hemolysis and endothelial damage increased postoperatively, CFHb did not independently predict AKI or improve predictive models, suggesting limited clinical utility as a biomarker.

AI-Driven Kidney Risk Prediction During Cardiac Surgery

Predicting Kidney Injury After Cardiac Surgery With Cardiopulmonary Bypass Using Machine Learning

March 22, 2026 No Comments

This study evaluates a machine learning (ML) model using electronic health record (EHR) data to predict acute kidney injury (AKI) after cardiac surgery. In 130 patients, the AI achieved strong predictive performance (AUROC 0.79 for AKI, 0.83 for 30-day kidney disease). The model enables early, automated risk stratification, offering a practical tool for proactive perioperative management and improved patient outcomes.

Global Cardiac Surgery Team Comparing HES vs Albumin

Comparison of 6% Hydroxyethyl Starch 130/0.4 vs 5% Albumin in Cardiopulmonary Bypass for Cardiac Surgery

March 21, 2026 No Comments

This meta-analysis of 12 studies (908 patients) compares 6% hydroxyethyl starch (HES 130/0.4) and 5% albumin in cardiac surgery with cardiopulmonary bypass. Results show no significant differences in blood loss, transfusion needs, ICU stay, or mortality. However, HES is associated with a significantly higher risk of acute kidney injury, raising concerns about its renal safety despite similar overall efficacy.

Monitoring Venous Pressure After Cardiac Surgery: Protecting Kidney Function

Exploring the Role of Central Venous Pressure in Cardiac Surgery-Associated Acute Kidney Injury: A Comprehensive Scoping Review

March 20, 2026 No Comments

This scoping review evaluates the association between central venous pressure (CVP) and acute kidney injury (AKI) following cardiac surgery, particularly CABG. Across 16 studies, elevated CVP consistently correlated with higher AKI risk, especially when combined with low mean arterial pressure. However, variability in CVP thresholds and study designs limits clinical standardization. The findings highlight CVP as a potential perioperative marker requiring further validation.

Kidneys at Risk During Cardiac Bypass Surgery

Risk Factors for Acute Kidney Injury After Coronary Artery Bypass Graft Surgery: A Systematic Review and Meta-Analysis

March 13, 2026 No Comments

Acute kidney injury (AKI) is a serious complication after coronary artery bypass graft (CABG) surgery. This systematic review and meta-analysis analyzed 17 observational studies including 33,809 patients to identify key predictors of AKI. Significant risk factors included advanced age, prolonged cardiopulmonary bypass duration, diabetes, intra-aortic balloon pump use, and red blood cell transfusion. Recognizing these risks may help clinicians improve perioperative management and reduce kidney complications after cardiac surgery.

Peripheral Versus Central Cannulation for Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO): A Meta-Analysis of Bleeding and Vascular Complications

February 16, 2026 No Comments

This meta-analysis of 15 studies (2,913 patients) compares peripheral and central cannulation strategies for VA-ECMO in refractory cardiogenic shock. Peripheral access significantly reduced major bleeding risk but increased limb ischemia. No meaningful differences were observed in infection, renal replacement therapy, or stroke. Findings support individualized cannulation decisions balancing bleeding risk against vascular complications.

Comparison of 6% Hydroxyethyl Starch 130/0.4 vs 5% Albumin in Cardiopulmonary Bypass for Cardiac Surgery

January 31, 2026 No Comments

This meta-analysis evaluated 12 randomized trials (908 patients) comparing 6% hydroxyethyl starch (HES) 130/0.4 with 5% albumin during cardiopulmonary bypass in cardiac surgery. Most outcomes—including blood loss, transfusion rates, ICU stay, hospital stay, and mortality—were similar between groups. However, HES use was associated with a significantly higher risk of acute kidney injury, highlighting renal safety concerns despite comparable hemodynamic efficacy.

Vasoplegic Syndrome in Cardiac Surgery: Bridging Therapeutic Gaps with Best Practices and Future Research

April 6, 2025 No Comments

This article explores vasoplegic syndrome (VS), a serious complication following cardiac surgery involving cardiopulmonary bypass. It discusses inconsistent definitions, risk factors, and treatment strategies. Methylene blue emerges as a promising therapy due to its ability to counteract the nitric oxide-cGMP pathway. The authors advocate for standardized definitions, early intervention, and large-scale trials to validate therapeutic protocols.